LeMaitre Vascular, Inc. (LMAT) Stock Analysis
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $101.33, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole- and limited-source suppliers; Analyst target reached - limited upside remaining.
LeMaitre Vascular develops, manufactures, and markets vascular devices and cryopreservation services for peripheral vascular, renal, and cardiovascular disease, selling primarily through a 160-person direct sales force in North America, Europe, and Asia Pacific. In 2025, ~95% of... Read more
Hold if already holding. Not a fresh buy at $101.33, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole- and limited-source suppliers; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — LeMaitre Vascular, Inc.
Latest news
- Comerica Bank Lowers Holdings in LeMaitre Vascular, Inc. $LMAT - MarketBeat — MarketBeat neutral
- Wells Fargo & Company Forecasts Strong Price Appreciation for LeMaitre Vascular (NASDAQ:LMAT) Stock - MarketBeat — MarketBeat positive
- LeMaitre Vascular (NASDAQ:LMAT) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat — MarketBeat positive
- Citizens raises LeMaitre Vascular stock price target on margin outlook By Investing.com - Investing.com Canada — Investing.com Canada positive
- LeMaitre Vascular (NASDAQ:LMAT) Issues Earnings Results - MarketBeat — MarketBeat neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole- and limited-source suppliers10-K Item 1A: 'We rely on sole- and limited-source suppliers for many of our important components and certain products, including our VascuCel and CardioCel biologic patch, Artegraft biologic vascular graft and Omniflow biosynthetic vascular graft.'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02LOWBridget Ross notified LeMaitre Vascular's Board on April 8, 2026 of her intent not to stand for re-election as a Class II director at the June 2, 2026 Annual Meeting. Her decision is not related to any disagreement with the Company.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $101.33, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: sole- and limited-source suppliers; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $103.31 (+2.0%), stop $94.24 (−7.5%), A.R:R 0.2:1. Score 5.7/10, moderate confidence.
Take-profit target: $103.31 (+2.0% upside). Target $103.31 (+2.0%), stop $94.24 (−7.5%), A.R:R 0.2:1. Stop-loss: $94.24.
Concentration risk — Supplier: sole- and limited-source suppliers; Analyst target reached - limited upside remaining; Expensive valuation.
LeMaitre Vascular, Inc. trades at a P/E of 37.1 (forward 31.0). TrendMatrix value score: 3.5/10. Verdict: Hold.
16 analysts cover LMAT with a consensus score of 4.0/5. Average price target: $119.
What does LeMaitre Vascular, Inc. do?LeMaitre Vascular develops, manufactures, and markets vascular devices and cryopreservation services for peripheral...
LeMaitre Vascular develops, manufactures, and markets vascular devices and cryopreservation services for peripheral vascular, renal, and cardiovascular disease, selling primarily through a 160-person direct sales force in North America, Europe, and Asia Pacific. In 2025, ~95% of net sales were generated through direct-to-hospital channels and 43% were international; no single hospital customer exceeded 2% of net sales.